Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage - Prime Therapeutics
Research & Publications
Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
Approximately 83,000 new bladder cancer cases are diagnosed in the U.S. in each year. Here’s a look at the recent advancements and treatment options for bladder cancer, as well as an update on the BCG shortage.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.
Latest News
Login Portals
Compliance / Legal
Company
© 2025 Prime Therapeutics LLC